prikaz prve stranice dokumenta Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE
  Download
PDF 3.3 MB
Scientific paper - Review paper
Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE
European Archives of Oto-Rhino-Laryngology, 276 (2019), 5; 1275-1281. https://doi.org/10.1007/s00405-019-05387-8
Suton, Petar; Skelin, Marko; Rakušić, Zoran; Dokuzović, Stjepan; Lukšić, Ivica

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Suton, P., Skelin, M., Rakušić, Z., Dokuzović, S. & Lukšić, I. (2019). Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. European Archives of Oto-Rhino-Laryngology, 276. (5), 1275-1281. doi: 10.1007/s00405-019-05387-8

Suton, Petar, et al. "Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE." European Archives of Oto-Rhino-Laryngology, vol. 276, no. 5, 2019, pp. 1275-1281. https://doi.org/10.1007/s00405-019-05387-8

Suton, Petar, Marko Skelin, Zoran Rakušić, Stjepan Dokuzović and Ivica Lukšić. "Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE." European Archives of Oto-Rhino-Laryngology 276, no. 5 (2019): 1275-1281. https://doi.org/10.1007/s00405-019-05387-8

Suton, P., et al. (2019) 'Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE', European Archives of Oto-Rhino-Laryngology, 276(5), pp. 1275-1281. doi: 10.1007/s00405-019-05387-8

Suton P, Skelin M, Rakušić Z, Dokuzović S, Lukšić I. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. European Archives of Oto-Rhino-Laryngology [Internet]. 2019 May [cited 2024 December 26];276(5):1275-1281. doi: 10.1007/s00405-019-05387-8

P. Suton, M. Skelin, Z. Rakušić, S. Dokuzović and I. Lukšić, "Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE", European Archives of Oto-Rhino-Laryngology, vol. 276, no. 5, pp. 1275-1281, May 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:503286. [Accessed: 26 December 2024]

Metadata
Title (english)Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE
AuthorPetar Suton
AuthorMarko Skelin
AuthorZoran Rakušić
AuthorStjepan Dokuzović
AuthorIvica Lukšić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Maxillofacial Surgery and Dentistry)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Surgery
Abstract (english)
Purpose: Human papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is a special entity among head and neck squamous cell carcinomas (HNSCCs). Given its favorable prognosis, one of the de-escalating strategies in the treatment of OPC includes the introduction of cetuximab (C225) instead of cisplatin (CDDP) in conjunction with radiotherapy. An updated meta-analysis of published studies has been performed, which directly compared the efficacy of CDDP vs. C225 given concurrently with radiotherapy as definitive treatment of p16-positive OPC. ----- Methods: A systematic literature search was performed for studies published between 2006 and 2018. A total of 1490 citations were obtained and 8 studies met inclusion criteria, with a total of 1665 patients. ----- Results: The data from seven studies were available for the analysis of 2-year overall survival (OS). Calculated pooled OR for CDDP-based chemoradiotherapy vs. C225-based bioradiotherapy, was 0.45 (P < 0.0001). The data from eight studies were available for the analysis of 2-year locoregional recurrence (LRR). Calculated pooled OR for CDDP-based chemoradiotherapy vs. C225-based bioradiotherapy was 0.35 (P < 0.0001). Patients receiving CDDP with irradiation had 2.2- and 2.9-fold decreased risk for death from any cause and LRR, respectively. ----- Conclusions: For patients with HPV-positive OPC, radiotherapy plus C225 showed inferior OS and higher LRR rates compared with radiotherapy plus CDDP. CDDP-based chemoradiotherapy should remain standard of definitive treatment of p16-positive OPC.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleEuropean Archives of Oto-Rhino-Laryngology
Numberingvol. 276, no. 5, pp. 1275-1281
p-ISSN0937-4477
e-ISSN1434-4726
DOIhttps://doi.org/10.1007/s00405-019-05387-8
URN:NBNurn:nbn:hr:105:503286
Publication2019-05
Document URLhttp://link.springer.com/10.1007/s00405-019-05387-8
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2021-03-17 11:20:20